Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 621 of 5804
-
New gel could outperform standard therapy for kidney disease
Disease control Recruiting nowThe goal of the Phase 3a part of this clinical trial is to determine the optimal dose that will be used in the Phase 3b part of this clinical trial. The goal of the Phase 3b part is to assess the efficacy of SNP-ACTH (1-39) Gel relative to rituximab in patients with primary membr…
Phase: PHASE3 • Sponsor: Cerium Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New hope for head and neck cancer: Three-Drug showdown after immunotherapy fails
Disease control OngoingThis phase II/III compares the standard therapy (chemotherapy plus cetuximab) versus adding bevacizumab to standard chemotherapy, versus combination of just bevacizumab and atezolizumab in treating patients with head and neck cancer that has spread to other places in the body (me…
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New cream offers hope for unbearable itch
Symptom relief CompletedThe purpose of this study is to evaluate the safety and tolerability of Ruxolitinib cream in participants with Prurigo Nodularis (PN).
Phase: PHASE3 • Sponsor: Incyte Corporation • Aim: Symptom relief
Last updated Jun 27, 2026 07:57 UTC
-
New eczema drug shows promise for kids in Long-Term trial
Disease control ENROLLING_BY_INVITATIONThe main purpose of this study is to assess the long-term safety and efficacy of lebrikizumab in participants 6 Months to \<18 years of age with moderate-to-severe atopic dermatitis. This study will last about 68 weeks and may include up to 16 planned visits. If participating in…
Phase: PHASE3 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New nasal vaccine aims to protect kids from RSV
⭐️ VACCINE ⭐️ Recruiting nowThis Phase 1/2a trial is a randomized, placebo-controlled trial to evaluate the safety, tolerability and immunogenicity of two ascending doses (10\^6 PFU and 10\^7 PFU) of intranasal BLB-201 (a recombinant parainfluenza virus type 5) administered in infants (8-24 months of age) a…
Phase: PHASE1, PHASE2 • Sponsor: Blue Lake Biotechnology Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 13:01 UTC
-
New heart device aims to zap away irregular rhythm
Disease control OngoingThis study will evaluate the safety and effectiveness of the Globe® Pulsed Field System for treating patients with symptomatic paroxysmal or persistent atrial fibrillation (AF).
Phase: NA • Sponsor: Kardium Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New combo therapy aims to shrink tough liver tumors
Disease control Recruiting nowAtezolizumab and bevacizumab was approve for advanced unresectable hepatocellular carcinoma (aHCC). Whether the additional of transartial chemobolization and hepatic artery infusion chemotherapy will improve the response rate for those patients is still unknown. This phase 2 clin…
Phase: PHASE2 • Sponsor: Sun Yat-sen University • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
Aspirin may shield new moms from breast cancer
Prevention Recruiting nowThis phase II trial tests whether low-dose aspirin can affect markers of inflammation in postpartum (after childbirth) women planning to have a breast biopsy. Chronic inflammation may increase the risk of postpartum related breast cancer. Low-dose aspirin is a non-steroidal anti-…
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with tough leukemia: antibody drug tafasitamab enters trial
Disease control Recruiting nowThe objective of the trial is to evaluate the safety, clinical toxicity and in vivo immunological effects of MOR00208 in pediatric patients with acute lymphoblastic leukemia who showed newly emerging or persistent MRD after a first stem cell transplantation, received stem cell tr…
Phase: PHASE1, PHASE2 • Sponsor: University Hospital Tuebingen • Aim: Disease control
Last updated Jun 27, 2026 09:02 UTC
-
Could a heart drug boost cancer treatment? new trial tests propranolol with chemo and immunotherapy
Disease control Recruiting nowThis phase II trial tests what effects the addition of propranolol to pembrolizumab and standard chemotherapy (mFOLFOX) may have on response to treatment in patients with esophageal or gastroesophageal junction cancer that cannot be removed by surgery and has spread to nearby tis…
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
New hope for lung cancer: immunotherapy cocktail under study
Disease control OngoingThe purpose of this study is to assess the antitumor activity, safety, and tolerability of tislelizumab plus investigational agent(s) with or without chemotherapy. This study is structured as a master protocol with separate sub- studies. Sub-study 1 includes participants with non…
Phase: PHASE2 • Sponsor: BeiGene • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New drug combo aims to control rare blood disease Long-Term
Disease control Recruiting nowThis study is researching an experimental treatment combination with two experimental drugs called pozelimab and cemdisiran. The study is focused on people with paroxysmal nocturnal hemoglobinuria (PNH). The aim of this study is to see how safe and effective the pozelimab + cemdi…
Phase: PHASE3 • Sponsor: Regeneron Pharmaceuticals • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
New drug combo aims to shrink bladder tumors before surgery
Disease control Recruiting nowErdafitinib (ERDA) alone or in combination with cetrelimab (CET) as neoadjuvant treatment (prior to surgery) in subjects with muscle-invasive bladder cancer (MIBC) whose tumours express Fibroblast Growth Factor Receptor (FGFR )gene alterations and are ineligible for or refuse cis…
Phase: PHASE2 • Sponsor: Spanish Oncology Genito-Urinary Group • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
Could a breast cancer drug combo treat rare tumors?
Disease control Recruiting nowThis clinical trial is looking at a combination of drugs called trastuzumab and pertuzumab. This combination of drugs is approved together as standard of care treatment for adult patients with breast cancer (often with other anti-cancer drugs). This means it has gone through clin…
Phase: PHASE2, PHASE3 • Sponsor: Cancer Research UK • Aim: Disease control
Last updated Jun 27, 2026 08:01 UTC
-
New drug cocktail aims to tackle tough pancreatic cancer
Disease control Recruiting nowThis phase I/II study tests how well zimberelimab and quemliclustat work in combination with chemotherapy (mFOLFIRINOX) in treating patients pancreatic adenocarcinoma that may or may not be able to be removed by surgery (borderline resectable) or that has spread to nearby tissue …
Phase: PHASE1, PHASE2 • Sponsor: Jonsson Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
Triple threat: Low-Dose radiation plus chemo and immunotherapy takes on tough lung cancer
Disease control OngoingThis is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have extensive-stage small cell lung cancer (ES-SCLC) and are chemot…
Phase: PHASE2 • Sponsor: Sichuan University • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Phone alerts and support groups aim to boost treatment success for dual epidemic
Disease control Recruiting nowThis is a prospective, adaptive, randomized controlled trial comparing the effectiveness of 4 intervention arms on a combined endpoint in adults with confirmed MDR-TB HIV initiating Bedaquiline-containing MDR-TB treatment regimens and on ART (integrase strand transfer inhibitor (…
Phase: NA • Sponsor: Columbia University • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New hope for COPD patients: drug aims to cut severe Flare-Ups
Disease control CompletedSubjects who completed either OBERON or TITANIA will be offered the opportunity to consent for this Multicentre, Double-blind, Randomised, Placebo controlled, Parallel Group, Phase 3, extension study to evaluate the safety and efficacy of Tozorakimab in adult participants with sy…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Experimental gene therapy aims to slow vision loss from dry AMD
Disease control CompletedThe purpose of this study is to evaluate change in geographic atrophy (GA) lesion growth of eyes treated with JNJ-81201887 compared to sham control.
Phase: PHASE2 • Sponsor: Janssen Research & Development, LLC • Aim: Disease control
Last updated Jun 27, 2026 11:01 UTC
-
Early preeclampsia test could save thousands of newborns and moms
Prevention Recruiting nowThe purpose of this study is to determine whether first-trimester screening for preeclampsia based on the FMF algorithm (a combination of maternal clinical, sonographic and biochemical parameters), improves maternal or perinatal health.
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Prevention
Last updated Jun 27, 2026 12:00 UTC